TC
DPLO

Trilogy Capital’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History

Trilogy Capital’s Portfolio DPLO Stock Details DPLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed -$3K – 676
2018
Q2 		$3K Hold
100
– – ﹤0.01% 441
2018
Q1 		$2K Buy
+100
New +$2.33K ﹤0.01% 419

Other funds holding DPLO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return

Trilogy Capital's DPLO Position: Q3 2018 in Review

Trilogy Capital sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q3 2018, closing a stake of 100 shares — an estimated $3K sold.

Trilogy Capital first reported a position in DPLO in Q1 2018 and held it in 2 quarters. The position peaked at $3K in Q2 2018. 178 funds tracked by Wall St. Rank hold DPLO as of Q3 2018.

  • Trilogy Capital reported no remaining DIPLOMAT PHARMACY, INC. position as of Q3 2018 after selling out during the quarter.
  • Trilogy Capital sold 100 DIPLOMAT PHARMACY, INC. shares in Q3 2018, an estimated $3K.
  • Trilogy Capital first reported a position in DIPLOMAT PHARMACY, INC. in Q1 2018 and held it in 2 quarters.
  • Trilogy Capital's DIPLOMAT PHARMACY, INC. position peaked at $3K in Q2 2018.
  • 178 funds tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q3 2018.

Based on Trilogy Capital's 13F filing for Q3 2018, filed 31 Oct 2018.